A Double-Blind Comparison of Granisetron and Placebo for the Treatment of Acute Migraine in The Emergency Department

Three hundred and ninety-seven patients who presented to the emergency department were screened for a randomized, double-blind, placebo-controlled study of iv granisetron (40 μg/kg or 80 μg/kg) in acute migraine. Twenty-eight patients fulfilled the stringent eligibility criteria and completed the study. Rescue medication was required 2 h post-infusion in 8 of 10 patients receiving granisetron 40 μg/kg, 5 of 10 patients receiving granisetron 80 μg/kg, and 6 of 8 patients receiving placebo. Significant improvement (p < 0.05) in headache pain (on a visual analogue scale and categorical scale) was observed in the 80–μg/kg group. Headache pain evaluated with the Hunter headache scale indicated improvement for the sensory and affective components of headache pain in both granisetron groups. Except for more nausea at 30 min in the placebo group, no significant differences were noted between treatments. All three treatments were well tolerated. Granisetron may be effective for acute migraine headache; however, further studies with increased patient numbers are required.